Narrow Results

In this work, the nanocarriers were synthesized utilizing the water/oil/water (W/O/W) emulsifying method to deliver Curcumin. A cutting-edge hydrogel nanocomposite, resulting from the fusion of Carboxymethyl cellulose (CMC), Agarose (Aga) and Molybdenum disulfide (MoS${}_2)$, presents groundbreaking ph-responsive solutions for drug delivery, with a focus on the controlled release of Curcumin (Cur), a robust element demonstrating exceptional prowess in neutralizing malignant cells. Incorporating MoS₂ into the CMC-modified Aga hydrogel introduces distinctive attributes that are amplified by the addition of Span 80 surfactant. This combination results in the creation of strong niosomal microemulsions, which helps Cur stay in the body longer. Adding hazelnut oil helps to make the microemulsion smaller without changing its round shape. FT-IR spectroscopy and XRD techniques were utilized in order to examine the microemulsions. Dynamic light scattering (DLS) tests showed that there are tiny particles in the nanocarriers. They are about 171.25 nm in size on average and have a PDI of 0.31. The round shape of the tiny particles was confirmed by looking at them with a special microscope called SEM. The zeta potential analysis showed that there is a positive charge on the surface, which is about 80.4 mV. Surprisingly, the drug was able to be loaded at 48% efficiency, with an entrapment efficiency of 86.75%, exceeding the previously reported values. Researchers tested how well Cur-loaded nanoparticles can kill cancer cells and also looked for any harmful effects on A549 and L929 cells. This discovery shows that using tiny carriers could be a good way to treat cancer.

This work extends a previous model that described the evolution of a tumor cord (a cylindrical arrangement of tumor cells, generally surrounded by necrosis, growing around a blood vessel of the tumor) under the activity of cell killing agents. In the present model we include the most relevant aspects of the dynamics of extracellular fluid, by computing the longitudinal average of the radial fluid velocity and of the pressure field. We still assume that the volume fraction occupied by the cells always keeps the same constant value everywhere in the cord. The necrotic region is treated as a "fluid reservoir". To improve the modelling of therapeutic treatment, we have subdivided the viable cell population into a proliferating and a quiescent subpopulation. The transitions between the two states are both permitted, and are regulated by rates depending on the local oxygen concentration. For simplicity, the rates of death induced by treatment are assumed to be known functions of the radial distance and time. Existence and uniqueness of the stationary state in the absence of treatment has been shown, as well as the existence and uniqueness of the evolution that arises following a cell killing treatment.

The goal of this study is the development of treatment schedules with increased selectivity in killing malignant cells as opposed to normal cells. The optimization is carried out on the basis of the mathematical model. The model describes the dynamics of proliferating cell population under in vivo periodic treatment with high doses of a phase-specific agent. On the basis of the model the effectiveness of various treatment schedules have been studied and optimal ones have been designed. When the mean cell-cycle times of normal and tumors cells differ significantly (as it is true for most natural tumors) the optimal schedules make it possible to increase considerably the selectivity of the treatment and to achieve important therapeutic benefit.

Anadis Licenses Antibody Technologies from ImmuCell

Abbott, Genentech and WEHI Collaborate to Discover New Anticancer Drugs

Living Cell Technologies and Barbara Davis Center Collaborate on Diabetes Clinical Trial Program

Avexa and Monogram Collaborate on HIV Drug

ChemGenex Launches Multi-site Omacetaxine Clinical Trial in AML Patients

Philips and Ascent Profit Deliver Digital Radiography Systems to China

OSI Systems Opens New Manufacturing Facility in China

MedPlus Launches Integrated Health Centers in India

Ranbaxy to Introduce INERSAN Brand in India and Nepal

Teleradiology Solutions Launches First Teleradiology Training Center in India

StemCyte Announces Joint Venture with Apollo Hospitals and Cadila Pharmaceuticals

Suven Life in Drug Research Deal with Eli Lilly

Dr Reddy's Enters into Drug Discovery Collaboration with 7TM Pharma

MorphoSys and Astellas to Develop Novel Antibody Therapies

Morphotek Signs Exclusive Licensing Agreement for Anticancer Antibody

bioMérieux and Hitachi High-Technologies Corporation Enter into Long-term Strategic Partnership

Kyowa Hakko and Amgen Enter into a Licensing Agreement for Anti-CCR4 Humanized Monoclonal Antibody

Stem Cell Therapy to Merge with Histostem

GlaxoSmithKline Opens New Research and Development Pilot Plant

CytoGenix and Taiwan Cobia Inc to Develop DNA Vaccines for Fish Viruses

Xenome's Library Licensed to MedImmune for a Discovery Partnership

pSivida Moving into Cardiovascular Drug Delivery Evaluation

Bringing Unique Automated Robotic Systems into China's Healthcare

WuXi AppTec Adopts H-Cube(R) from ThalesNano for Laboratory-based Hydrogenation

Orexo's Abstral Granted to NovaMed to Break into China's Market

Dow India and Royal Castor Collaborate in Castor Oil R&D

Arcadia Biosciences and Advanta to Develop Nitrogen Use Efficient Sorghum

First Plasma Fractionation Facility in India to Meet Self-sufficiency

Daiichi Sankyo Collaborates with The Kitasato Institute to Control Emerging Infectious Diseases

JAK2 Inhibitors Developed by S*BIO Target Inroads to North American and European Markets

Abbott Based its First Asian R&D Site in Singapore

Singapore and France Tie Up to Build Antibody-Based Therapies

AsiaMedic Forges Partnership to Expand into Middle East Market

South Korean and U.S. Biopharma Conduct Phase II JX-594 Trial for Liver Cancer

Arana Announces Issuance of Key European Patent for Evibodies.

Living Cell Technologies Reports Interim Results Showing Sustained Beneft with DIABECELL^® Implants for Insulin Dependent Diabetes.

Topical Microbicide Field Receives Boost with Human Effcacy Result.

WuXi PharmaTech Honored on the Deloitte Technology Fast 500 Asia Pacifc 2008 List for the Fifth Consecutive Year.

Syngenta Enters into Research Collaboration with Anhui Academy, China.

Bayer Schering Pharma to Invest 100 Million Euro in China to Build a Global R&D Center.

Dow AgroSciences, China National Rice Research Institute Announce Collaboration on Rice Research.

World's First Robotic Radiosurgery System Introduced at Apollo Hospitals.

Fortis Ties up with International Oncology.

Apotex and Intas Biopharma Partner to Develop Biosimilars.

Abbott Opens New Pediatric Nutrition Manufacturing Facility in Singapore.

Schering-Plough Opens First R&D Centre in Singapore.

Hyfux Still Expanding.

GSK to Commit $1.3 Million to Singapore Institute's Vaccine Development Projects.

Invida to Market Breakthrough Anti-nausea Patch in Asia Pacifc.

NUS Partners International Rice Research Institute to Address Global Food Security Challenge.

Singapore Research Organizations Team up to Advance Drug Discovery Using Brain Tumor Stem Cells.

Benitec MOU with Biomics Biotechnologies China.

Arkema & Aussie Chemeq Sign Manufacturing Cooperation Agreement.

AstraZeneca and Mental Health Research Institute in Australia Announce Collaboration to Improve Early Detection of Alzheimer's Disease.

Avexa Gets CSIRO Investment.

Living Cell Technologies' Encapsulated Choroid Plexus Cells May Be Used To Treat Hearing Loss.

Sundia MediTech Acquires Protein Folding Technology.

Beijing Cancer Hospital Introduces Fast and Precise RapidArc Radiotherapy Cancer Treatments.

Zydus Cadila and Karo Bio's Research Collaboration has Generated Promising Lead Compounds.

ICON Acquires Veeda Laboratories Limited.

Novavax-Cadila to Conduct Swine Flu Clinical Trials.

Axygen & Astellas form JV to Develop Protein Drugs.

Rexahn, KRICT to Develop Anti-Cancer Drugs.

Japan's Largest Pharmaceutical Firm Opens Regional HQ in Singapore.

CSIRO and Circadian Collaborate in Oncology R&D.

Successful Trials in Bone Marrow Regeneration Using Cord Blood.

Pfizer China and BMP Sunstone Venture into Women's Healthcare Product.

Novartis Acquires Zhejiang Tianyuan to Expand Human Vaccines Presence in China.

Carbon Nanotechnology for Target Drug Delivery System Launched in India.

Cipla Launches Antiflu to Combat Influenza.

Tokyo CRO and Ecron Acunova in Alliance to Strengthen Global Network.

World's First Oral Jelly for Alzheimer's Disease Treatment.

Leading Japanese and Swedish Biotech Firms Seal Antibody Deal.

Caduet^® Combination Tablets Launched in Japan.

Spectrum Teams Up with Korea's Handok on Apaziquone.

Biologics, CEVEC Sign Agreement for Using Human CAP Technology.

Chaperone Technologies and MerLion Pharmaceuticals in Antimicrobials Collaboration.

Quintiles Expands Asia-Pacific Headquarters in Singapore.

NCKU and ScinoPharm Taiwan Establish University-Industry Cooperation.

What it takes to be a Technopreneur & Sir Tom Blundell

Fumarase: A Novel Molecular Target in Cancer Treatment

AXA Assistance on Regenerative Medicine: An interview with Serge Morelli and Xavier Blanchard

Scientists in Guangzhou engineered pig model of Huntington’s disease

Heart-on-a-chip device to aid drug screening

Nanozymes to target tumor cells

Cancer stem cell therapy breakthrough

Hong Kong researchers invent antibody drug for HIV-I prevention

SNAB technology to mark tumor cells during cancer surgeries

Draft genome of tea plant sequenced

International Earth BioGenome Project proposed to sequence DNA of all known species on Earth

Chinese pharma regulatory reforms will help to attract foreign investment

Merck receives patent for CRISPR Technology in China

STA Pharmaceuticals to build new R&D center in Shanghai

China approves norovirus vaccine for clinical trial.

Public hospitals in China receive increasing government funds.

Tax incentives for top talents in the Greater Bay Area.

National Health Commission of China calls for production of generic drugs.

AI offers breakthrough in cancer diagnosis.

Drug-free theranostic agent for cancer treatment.

E-healthcare innovation competition finishes in Shanghai.

Bioindustry Convention held in Guangzhou.

China’s State Council publishes new regulations on the management of human genetic resources.

Chinese institutions ranked high in Nature Index.

US$120 million joint venture in China to develop innovative cell therapies for cancer.

Digital mental health strategy in China.

The following topics are under this section:

• Asia-Pacific — MIT's research enterprise in Singapore (SMART) launches new research group, boosting nation's cell therapy R&D
• Asia-Pacific — Potential cancer treatment strategies for humans from mechanisms behind low cancer occurrence in bats
• Asia-Pacific — Singapore scientists uncover mechanism behind development of viral infections
• Asia-Pacific — Exosomes found to aid in fighting Dengue infection
• Asia-Pacific — National platforms created to accelerate Singapore's drug development efforts
• Rest of the World — Cybersecurity company threat report details cyberattacks targeting the healthcare industry
• Rest of the World — Artificial intelligence – designed influenza vaccine begins clinical trials in the US
• Rest of the World — Clinical – stage biotechnology company presents Murlentamab phase II study results in colorectal cancer

The photosensitizing and pharmacokinetic properties of porphyrin-type compounds have been investigated for nearly a century. In the last decade, two porphyrin derivatives were approved in the U.S.A. and in several other countries for the photodynamic treatment of various lesions. An overview of the different mechanisms for preferential porphyrinoid localization in malignant tumors is presented herein. Several uptake pathways are possible for each photosensitizer, which are determined by its structure, mode of delivery and tumor type. Comparisons of the different mechanisms and correlations with the structure of the sensitizer are presented. Current delivery systems for porphyrin sensitizers are described, as well as recent strategies for enhancing their tumor-specificity, including conjugation to a carrier system that selectively targets a tumor-associated receptor or antigen.

Novel peripherally and non-peripherally 3-methylindole-substituted zinc phthalocyanine derivatives were synthesized as photosensitizers for photodynamic therapy in cancer treatment. The photophysical, photochemical and photobiological properties of targeted phthalocyanines were also investigated. For this purpose, the fluorescence and singlet oxygen quantum yields, and fluorescence lifetime values of the final compounds were determined in DMF solutions. The phototoxicity and cytotoxicity of the phthalocyanine complexes were tested against the invasive human breast cancer cell line (MDA-MB-231) for determination of their photosensitizing ability in the area of photodynamic therapy. It was revealed that while peripherally 3-methylindole-substituted phthalocyanine was found to be toxic for cells in both dark and light conditions, its non-peripherally substituted phthalocyanine analogue significantly caused cell death following light irradiation. A preliminary assay suggested that the non-peripherally linked phthalocyanine could be a suitable candidate for cancer treatment via photodynamic therapy techniques.

Cancer is the second major threat to human health, and more effective cancer therapy strategies are imperative. With the development of nanotechnology, mesoporous silica-based nanoparticles (MSNs) have seen unprecedented development in cancer treatment, such as drug delivery, bioimaging and biosensing. They have received extensive attention because of their easy preparation, adjustable morphology, homogeneous pore structure, high surface areas and good biocompatibility. However, cumulative toxicity for organism caused by the low degradability of MSNs heavily hinders their translation from bench to beside. Enhancing the degradability of MSNs has provided an effective solution to solve this problem. This review aims at summarizing the effective strategies utilized to regulate the degradability of MSNs during the last few years, giving a complete overview on the recent progress and remaining challenges of degradable MSNs.

Iron oxide-based magnetic nanoparticles (IONPs) have received remarkable attention in a wide range of applications because of their unique physicochemical properties’ inheritance to the nanoscale. Among these nanoparticles (NPs), superparamagnetic iron oxide nanoparticles (SPIONs), as powerful noninvasive NPs, are widely used in nanomedicine applications such as targeted drug/ gene delivery, magnetic separation, cancer therapy, and magnetic resonance imaging (MRI) hyperthermia because of their superparamagnetic activity and remarkable small size. The synthesis of SPIONs and surface modification of these NPs for biological applications is an interesting research topic. These NPs have high magnetic susceptibility, a single magnetic domain, and a controlled magnetic behavior due to the SPION superparamagnetic feature. This review aims to explore the recently developed synthetic routes of SPIONs and show the best parameters to prepare SPIONs using pulsed laser ablation in liquid “PLAL” for biomedical applications. Furthermore, we highlight the properties, coating, and functionalization of SPIONs and their importance for biomedical applications, including targeted drug delivery and cancer therapy.

Study of nanoparticles has attracted the immense attention of researchers because of their wide applications in the medicine, chemical industries, and biotechnology. This paper highlights that plants and microbes can be a source of bio-compounds in nanoparticle synthesis in place of toxic chemicals. As this is an environmentally friendly approach following the principles of green synthesis which is cheap and is not toxic. Both sources provide antioxidant, anticancer, and antimicrobial properties which hold great importance in the manufacturing of NPs. This review aims to bring together the diversity of synthesized metallic nanoparticles mediated by plant extracts, fungi, algae, bacteria and yeasts. All the mentioned bio-resources contain biomolecule which includes protein and enzyme which serves the twin action of both reduction and capping of the synthesized nanoparticles. The synthesized NPs are characterized by using UV-visible spectrometry, FT-IR, XRD, TEM, SEM and EDX. Also, the biomedical application of the synthesized NPs is explored in the treatment of cancer.

Iron oxide nanoparticles (NPs) have been a very appealing choice in magnetic-mediated hyperthermia for cancer therapy. The responses of NPs to hyperthermia as a cancer treatment method are complex and variable. Herein, the heating properties of the casein-coated magnetic NPs (MNPs) under an alternating magnetic field were investigated. The casein-coated MNPs were synthesized via one-pot chemical method. The casein-coated MNPs were characterized using transmission electron microscopy (TEM), scanning electron microscopy (SEM), energy dispersive X-ray spectroscopy (EDAX), Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), zeta potential, dynamic light scattering (DLS), and vibrating sample magnetometer (VSM) analysis. TEM images of casein-coated MNPs show that their shapes are spherical and their core sizes are between 20nm and 25nm. The FTIR and EDAX results confirmed the presence of casein on the surface of MNPs. The VSM shows the superparamagnetic nature of iron oxide and casein-coated iron oxide NPs with the magnetic saturation of 60emu/g and 44.86emu/g, respectively, at room temperature. Furthermore, hyperthermia tests for casein-coated MNPs with various concentrations and frequencies are performed. Hyperthermia results show that lower concentrations of casein-coated MNPs dispatch higher heating into their surrounding medium, whereas maximum specific absorption rate occurs at the concentration of 1mg/mL for the frequency of 150kHz. Findings of this study suggest that casein-coated MNPs have great potential as an anticancer agent in hyperthermia cancer therapy.

Cancer is a devastating disease that takes the lives of hundreds of thousands of people every year. Due to disease heterogeneity, standard treatments, such as chemotherapy or radiation, are effective in only a subset of the patient population. Tumors can have different underlying genetic causes and may express different proteins in one patient versus another. This inherent variability of cancer lends itself to the growing field of precision and personalized medicine (PPM). There are many ongoing efforts to acquire PPM data in order to characterize molecular differences between tumors. Some PPM products are already available to link these differences to an effective drug. It is clear that PPM cancer treatments can result in immense patient benefits, and companies and regulatory agencies have begun to recognize this. However, broader changes to the healthcare and insurance systems must be addressed if PPM is to become part of standard cancer care.

Doxorubicin (DOX) is an antibiotic anthracycline extensively used in the treatment of different malignancies, such as breast cancer, lymphomas and leukemias. The cardiotoxicity induced by DOX is one of the most important pathophysiological events that limit its clinical application. Accumulating evidence highlights mitochondria as a central role in this process. Modulation of mitochondrial functions as therapeutic strategy for DOX-induced cardiotoxicity has thus attracted much attention. In particular, emerging studies investigated the potential of natural mitochondria-targeting compounds from Traditional Chinese Medicine (TCM) as adjunct or alternative treatment for DOX-induced toxicity. This review summarizes studies about the mechanisms of DOX-induced cardiotoxicity, evidencing the importance of mitochondria and presenting TCM treatment alternatives for DOX-induced cardiomyopathy.